Why $ABEO at $5.30 is a massive fundamental anomaly ready to ignite a historical Short Squeeze

Here is the cold, hard data on why the current valuation is a complete joke, and exactly when the shorts are going to get trapped.
**1. The Insane Enterprise Value (EV) Discount**
**Market Cap:** \~$330M (at \~$5.37/share).

**Cash & Short-term Investments:** $168.3M (As of March 31, 2026).

**Enterprise Value (EV):** **$161.7M** Wall Street is valuing their entire FDA-approved manufacturing facility, their active commercial launch, their new solid tumor T-cell platform (ABO-701), and a functional commercial monopoly at just $161M. Bankruptcy or near-term dilution risk is mathematically **0%**.

**2. High-Octane Operating Leverage**
In Q1 2026, Zevaskyn generated **$8.72M in revenue** (pulverizing the consensus forecast of $4.62M by over 88%).
**The kicker:** That $8.72M came from just **3 patients** ($2.9M average per patient).

**The margins:** Cost of sales was only $2.7M, meaning they are pulling a massive **\~69% gross margin** on their first treatments. With quarterly recurring fixed costs (SG&A + core R&D) stabilized around $22M, their commercial break-even point is just **11 patients per quarter**.

**3. The Shorts are Trapped in a 22-Day Chokehold**
According to official NASDAQ data, the **Short Interest stands at a massive 30.64% of the float** (16.49 million shares sold short). Because of the low average daily volume, the **Days to Cover is a staggering 22.5 days** (fintel shows a short volume ratio consistently above 50-60% over the last few days). They cannot squeeze through the exit door quietly.
**Timeline of the Squeeze: When does the fuse ignite?**
The disconnect exists because we are in a temporary visibility gap: the company has expanded its Qualified Treatment Centers (QTCs) to 6 active sites, but the cash hasn't fully hit the balance sheet yet. The short squeeze is highly likely to trigger in 3 distinct steps this year:
**Step 1: The June 2026 Profitability Floor.** Management explicitly reiterated on the May 13 call that they anticipate hitting **monthly net profitability starting June 2026**. Once June prints green, the "cash burn" narrative is dead, creating an unbreakable floor around $5.00 - $5.50. Borrow rates will start eating the shorts alive.

**Step 2: The Mid-August Q2 Earnings Trigger.** In Q1, all $8.72M came from only 2 active centers. For Q2, management confirmed **1 patient is already treated, 1 is in manufacturing, and 6 more are scheduled/expected for biopsies**. That's a pipeline of 7 to 8 patients for Q2, projecting revenue near **$20M - $23M**. Printing a sequential 100%+ revenue growth will cut the quarterly net loss in half. Algos will buy aggressively, triggering margin calls for weak shorts as soon as we breach technical resistance at $7.50, pushing the stock to $10.

**Step 3: November Q3 Capitulation.** As their network scales toward 15 active centers by year-end, Q3 will be the first full quarter displaying structural net profitability. Trapped by a 22-day exit timeline, institutional shorts will be forced into a cascading buy-back panic.

**Bottom line:** Krystal Biotech ($KRYS), their direct competitor with a lifelong chronic application gel, is sitting on a **$9.1B market cap**. Abeona's curative, one-shot cell therapy just needs to capture a fraction of that execution to reach a $1B valuation, pushing the stock straight to **$15+**.
The spring is coiled tight. The August earnings will be the catalyst. Positioned before the crowd.